Medicus Pharma Receives FDA Feedback on Phase 2 Clinical Protocol of SKNJCT-003
Dr. Raza Bokhari, CEO of Medicus Pharma, shares updates on the company's interaction with the FDA. FDA feedback on study findings and regulatory submissions. Commitment to advancing innovative therapies and meeting regulatory guidelines.
The FDA's feedback on Medicus Pharma's study findings could impact the development of a potential therapeutic option. This news highlights the company's commitment to meeting regulatory guidelines and advancing innovative therapies, ultimately aiming to bring impactful treatments to patients in need.
